Involvement of necroptosis, a newly recognized cell death type, in steroid-induced osteonecrosis in a rabbit model

Toru Ichiseki1, Shusuke Ueda1, Yoshimichi Ueda2

  • 1Department of Orthopaedic Surgery, Kanazawa Medical University, Daigaku 1-1, Uchinada, Kahoku-gun, Ishikawa, 920-0293, Japan.

Insights

Programmed necrosis (necroptosis) contributes to steroid-induced osteonecrosis. Inhibiting necroptosis with necrostatin-1 significantly reduced osteonecrosis rates, suggesting it as a potential therapeutic target.

Area of Science:

  • Cellular Biology
  • Pathology
  • Pharmacology

Background:

  • Steroid-induced osteonecrosis is a debilitating condition.
  • The precise mechanisms underlying its development are not fully understood.
  • Programmed necrosis (necroptosis) has emerged as a potential contributor.

Purpose of the Study:

  • To investigate the role of necroptosis in steroid-induced osteonecrosis.
  • To evaluate the efficacy of necrostatin-1, a necroptosis inhibitor, in preventing steroid-induced osteonecrosis.

Main Methods:

  • A rabbit model of steroid-induced osteonecrosis was established using methylprednisolone.
  • Animals were treated with or without necrostatin-1.
  • Femoral bone samples were analyzed histopathologically and via Western blotting for RIP1 and RIP3 expression.

Main Results:

  • Steroid administration resulted in a 70% osteonecrosis rate.
  • Treatment with necrostatin-1 completely prevented osteonecrosis (0% rate).
  • Western blotting confirmed increased RIP1 and RIP3 expression in steroid-treated animals, indicating necroptosis activation.

Conclusions:

  • Necroptosis, mediated by RIP1 and RIP3, plays a significant role in steroid-induced osteonecrosis.
  • Inhibiting necroptosis with necrostatin-1 effectively prevents the condition.
  • Necroptosis represents a promising novel therapeutic target for steroid-induced osteonecrosis.

Related Concept Videos